Ultrasensitive Upconversion Nanoparticle Immunoassay for Human Serum Cardiac Troponin I Detection Achieved with Resonant Waveguide Grating

Modulation of Aggregation of Covalent Organic Framework Nanosheets with Aggregation-Induced Emission Activity for Ultrasensitive No-Wash Fluorescent Immunosensor

No-wash fluorescence immunosensors are favored because of their simple operation and precise results. However, cleverly designing two fluorescent materials so that their interaction through antigen-antibody specific binding to produce significant fluorescence changes poses a considerable challenge to the design of immunosensors. Herein, covalent organic framework nanosheets (CONs) with aggregation-induced emission (AIE) luminogens (AIEgens) were synthesized to regulate the aggregation of AIEgens through antigen-antibody binding for an ultrasensitive no-wash fluorescence immunosensor. The two-dimensional (2D) CONTFBE-PDAN exhibited excellent AIE activity. A Pt nanoparticle (PtNP)-modified AIE-CONTFBE-PDAN was designed as a signal amplifier, in which the PtNPs were used to bind antibody (Ab) via Pt-N/Pt-S bonds. After the sandwich immunocomplexes were formed by the antigen-antibody interaction, a more compact stacking assembly maximizes the restriction of intramolecular rotation, restriction of intramolecular vibration, restriction of intramolecular motion, and conformational planarization. This optimizes the spatial alignment required for efficient AIE, thereby yielding a strong fluorescence response. Using carcinoembryonic antigen 19-9 (CA 19-9) as a model tumor marker, a no-wash sandwich-type fluorescent immunosensor was constructed. Since a crystalline 2D AIE-CONTFBE-PDAN contains lots of AIEgens, the sensitivity of the fluorescence immunosensor is expected to improve greatly. The no-wash sandwich-type immunosensor showed good performance for CA 19-9 with a linear range of 0.01 mU/mL to 10 U/mL and a detection limit of 3.3 μU/mL (S/N = 3), which was satisfactory in real samples. To the best of our knowledge, this is the first time that AIE-CONs have been used for fluorescence immunosensing, which provides a new perspective for the trace detection of tumor markers.

A Patient-Centered Approach in Sensor Science: Embracing Patient Engagement for Translational Clinical Technologies

With the goal of impacting patient quality of life and outcomes, sensor science offers significant potential to revolutionize healthcare by providing advances in the detection of molecular biomarkers for personalized clinical technologies. The sensor community has achieved significant technical advancements that can impact diagnostics, health monitoring, and disease treatment; however, many sensor innovations remain confined to the laboratory, failing to bridge the translational gap between research and real-world clinical applications. This perspective presents a new direction for the sensor community, where sensor development centers on the needs and experiences of the primary beneficiaries: the patients. We provide guidelines and resources for researchers to engage with patients early and continuously throughout the research process to inform sensor specifications and better align sensor technologies with real-world clinical needs, improving their adoption and impact. We also present examples for implementing a patient-centered approach in sensor development and planning for patient engagement in sensor research. In the design of impactful sensors for patients, researchers must expand focus beyond technical specifications to embrace a patient-centered approach, which will likely lead to new opportunities for collaboration and evolution in the sensor science community.

Multifunctional theranostic glyconanoprobes for synergistic eradication of breast cancer

Theranostic agents hold great promise for personalized medicine by combining diagnostic and therapeutic functions. Herein, two novel multifunctional theranostic glyconanoprobes targeting breast cancer were engineered for synergistic dual chemo-gene therapy and triple chemo-gene-photothermal therapy. Upconversion nanoparticles (UCNPs) were prepared and coated with a Dox-loaded glycopeptide polymer (P-Dox) to form UCNP@P-Dox for improving stability. UCNP@MP-Dox equipped for triple therapy was prepared by combining UCNP@P-Dox with magnetic (Fe3O4, M) nanoparticles with photothermal properties. To regulate the expression of the anti-apoptotic Bcl-2 protein, both UCNP@P-Dox and UCNP@MP-Dox were loaded with anti-Bcl-2 siRNA. Impressive photothermal efficiency and good MRI contrast were demonstrated in preliminary evaluations. Moreover, the UCNP@P-Dox/siRNA nanoprobe for dual therapy was shown in preclinical studies to significantly increase anti-tumor efficacy. In vivo experiments in tumor-induced mice showed nanoprobe accumulation in tumors and enhanced antitumor efficacy with combinatorial therapy over Dox and siRNA alone. This study demonstrates the tumor-targeting capability of multifunctional theranostic glyconanoprobes, establishing chemo-gene synergy as a potent therapeutic strategy for breast cancer.

Nanoparticle biosensors for cardiovascular disease detection

Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality. To date, with the combination of developed nanoparticles, several optical and electrochemical-based biosensors have successfully been used detection of CVD biomarkers. Nanomaterials, when introduced as the modifiers of sensor surfaces like electrodes and gold chips, can result in the more comprehensive and more effective immobilization of capture molecules, ie, antibodies, aptamers and other ligands, due to their large surface area. In recent years, inorganic nanoparticles have regularly been used in the production of biosensors mostly due to their excellent response intensification, adaptable functionalization chemistry, shape control, good biocompatibility, and great stability. In this review, we discuss the application of different kinds of nanoparticles for the sensitive and specific detection of CVD biomarkers.

Trends in Aptasensing and the Enhancement of Diagnostic Efficiency and Accuracy

The field of healthcare diagnostics is navigating complex challenges driven by evolving patient demographics and the rapid advancement of new technologies worldwide. In response to these challenges, these biosensors offer distinctive advantages over traditional diagnostic methods, such as cost-effectiveness, enhanced specificity, and adaptability, making their integration with point-of-care (POC) platforms more feasible. In recent years, aptasensors have significantly evolved in diagnostic capabilities through the integration of emerging technologies such as microfluidics, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems, wearable devices, and machine learning (ML), driving progress in precision medicine and global healthcare solutions. Moreover, these advancements not only improve diagnostic accuracy but also hold the potential to revolutionize early detection, reduce healthcare costs, and improve patient outcomes, especially in resource-limited settings. This Account examines key advancements, focusing on how scientific breakthroughs, including artificial intelligence (AI), have improved sensitivity and precision. Additionally, the integration of aptasensors with these technologies has enabled real-time monitoring and data analysis, fostering advances in personalized healthcare. Furthermore, the potential commercialization of aptasensor technologies could increase their availability in clinical settings and support their use as widespread solutions for global health challenges. Hence, this review discusses technological improvements, practical uses, and prospects while also focusing on the challenges surrounding standardization, clinical validation, and interdisciplinary collaboration for widespread application. Finally, ongoing efforts to address these challenges are key to ensure that aptasensors can be effectively implemented in diverse healthcare systems.

Near-infrared-driven dual-photoelectrode photoelectrochemical sensing for fumonisin B1: Integrating a photon up-conversion bio-photocathode with an enhanced light-capturing photoanode

Fumonisin B1 (FB1), the most prevalent and highly toxic mycotoxin within the fumonisins family, poses threats to humans, especially in children and infants, even at trace levels. Therefore, it is essential to design an easy and sensitive detection strategy. Herein, a brand-new dual-photoelectrode photoelectrochemical (PEC) sensing platform for FB1 detection under near-infrared irradiation was unveiled. This platform integrated a photon up-conversion bio-photocathode substrate (UCNPs/Au/CuInS2, UCNPs: NaYF4: Yb3+, Er3+, Nd3+) and used a SnO2/SnS2@Bi/Bi2S3 heterojunction photoanode to greatly enhance light capture. Additionally, ZnO coated with polydopamine (ZnO@PDA) was utilized as a signal inhibitor. The restoration of photocurrent occurred due to the strong binding affinity between FB1 and its aptamer (FB1-Apt), facilitating the dissociation of FB1-Apt/ZnO@PDA from the photoelectrode. The PEC sensing performance and the electron transfer process were thoroughly examined. The developed "signal-restoration" PEC aptasensor exhibited a wider dynamic linear range from 1.0 × 10-3 to 1.0 × 102 ng/mL, with a lower limit of detection (0.13 pg/mL). It has demonstrated excellent practical detection performance in unspiked real samples, such as corn paste, with the FB1 enzyme-linked immunosorbent assay (ELISA) Kit serving as a reference, indicating its potential for routine analysis of other mycotoxins. Thus, this research establishes a feasible dual-photoelectrode PEC framework for the effective detection of mycotoxins and other hazardous substances.

Just-in-Time Generation of Nanolabels via In Situ Biomineralization of ZIF-8 Enabling Ultrasensitive MicroRNA Detection on Unmodified Electrodes

Nanolabels can enhance the detection performance of electrochemical biosensing methods, yet their practical application is hindered by complex preparation, batch-to-batch variability, and poor long-term storage stability. Herein, we present a novel electrochemical method for miRNA detection based on the just-in-time generation of zeolitic imidazolate framework-8 (ZIF-8) nanolabels initiated by nucleic acids. In this design, the target miRNA-21 is captured with magnetic beads and polyadenylated by Escherichia coli Poly(A) polymerase (EPP), producing miRNA-21 molecules with poly(A) tails (miR-21-poly(A)). These molecules are then adsorbed onto a bare gold electrode (AuE) surface via adenine-gold affinity interactions, serving as nucleation sites for the rapid in situ formation of ZIF-8 nanoparticles. The ZIF-8 nanoparticles function as signal labels, impeding electron transfer at the electrode interfaces and thereby generating a notable electrochemical signal. The developed method demonstrated exceptional sensitivity, with a detection limit (LOD) as low as 2.3 aM and a linear detection range from 10 aM to 1000 fM. The practical application of the developed method was validated by using it to evaluate miRNA-21 expression levels in various biological samples, including cell lines, tumor tissues, and clinical blood samples from non-small cell lung cancer (NSCLC) patients. This approach simplifies the detection process by eliminating the need for presynthesized nanomaterials and premodified electrodes. Its simplicity and high sensitivity make this method a promising tool for point-of-care testing and a wide range of biomedical research applications.

Development of a carboxymethyl chitosan functionalized slide for small molecule detection using oblique-incidence reflectivity difference technology

Label-free optical biosensors have become powerful tools in the study of biomolecular interactions without the need for labels. High throughput and low detection limit are desirable for rapid and accurate biomolecule detection. The oblique-incidence reflectivity difference (OI-RD) technique is capable of detecting thousands of biomolecular interactions in a high-throughput mode, specifically for biomolecules larger than 1000 Da. In order to enhance the detection capability of OI-RD for small molecules (typically < 500 Da), we have developed a three-dimensional biochip that utilized carboxymethyl chitosan (CMCS) functionalized slides. By investigating various factors such as sonication time, protein immobilization time, CMCS molecular weight, and glutaraldehyde (GA) functionalization time, we have achieved a detection limit of 6.8 pM for avidin (68 kDa). Furthermore, accurate detection of D-biotin with a molecular weight of 244 Da has also been achieved. This paper presents an effective solution for achieving both high throughput and low detection limits using the OI-RD technique in the field of biomolecular interaction detection.

Luminescent photon-upconversion nanoparticles with advanced functionalization for smart sensing and imaging

Photon-upconversion nanoparticles (UCNP) have already been established as labels for affinity assays in analog and digital formats. Here, advanced, or smart, systems based on UCNPs coated with active shells, fluorescent dyes, and metal and semiconductor nanoparticles participating in energy transfer reactions are reviewed. In addition, switching elements can be embedded in such assemblies and provide temporal and spatial control of action, which is important for intracellular imaging and monitoring activities. Demonstration and critical comments on representative approaches demonstrating the progress in the use of such UCNPs in bioanalytical assays, imaging, and monitoring of target molecules in cells are reported, including particular examples in the field of cancer theranostics.

Optical nanomaterial-based detection of biomarkers in liquid biopsy

Liquid biopsy, which is a minimally invasive procedure as an alternative to tissue biopsy, has been introduced as a new diagnostic/prognostic measure. By screening disease-related markers from the blood or other biofluids, it promises early diagnosis, timely prognostication, and effective treatment of the diseases. However, there will be a long way until its realization due to its conceptual and practical challenges. The biomarkers detected by liquid biopsy, such as circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), are extraordinarily rare and often obscured by an abundance of normal cellular components, necessitating ultra-sensitive and accurate detection methods for the advancement of liquid biopsy techniques. Optical biosensors based on nanomaterials open an important opportunity in liquid biopsy because of their enhanced sensing performance with simple and practical properties. In this review article, we summarized recent innovations in optical nanomaterials to demonstrate the sensitive detection of protein, peptide, ctDNA, miRNA, exosome, and CTCs. Each study prepares the optical nanomaterials with a tailored design to enhance the sensing performance and to meet the requirements of each biomarker. The unique optical characteristics of metallic nanoparticles (NPs), quantum dots, upconversion NPs, silica NPs, polymeric NPs, and carbon nanomaterials are exploited for sensitive detection mechanisms. These recent advances in liquid biopsy using optical nanomaterials give us an opportunity to overcome challenging issues and provide a resource for understanding the unknown characteristics of the biomarkers as well as the mechanism of the disease.